Correlation Between 09247XAS0 and Spyre Therapeutics

Can any of the company-specific risk be diversified away by investing in both 09247XAS0 and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 09247XAS0 and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between BLK 21 25 FEB 32 and Spyre Therapeutics, you can compare the effects of market volatilities on 09247XAS0 and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 09247XAS0 with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 09247XAS0 and Spyre Therapeutics.

Diversification Opportunities for 09247XAS0 and Spyre Therapeutics

0.23

Correlation Coefficient

09247XAS0  Spyre Therapeutics

Modest diversification

The 3 months correlation between 09247XAS0 and Spyre is 0.23. Overlapping area represents the amount of risk that can be diversified away by holding BLK 21 25 FEB 32 and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and 09247XAS0 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BLK 21 25 FEB 32 are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of 09247XAS0 i.e., 09247XAS0 and Spyre Therapeutics go up and down completely randomly.

Pair Corralation between 09247XAS0 and Spyre Therapeutics

Assuming the 90 days trading horizon BLK 21 25 FEB 32 is expected to under-perform the Spyre Therapeutics. But the bond apears to be less risky and, when comparing its historical volatility, BLK 21 25 FEB 32 is 5.6 times less risky than Spyre Therapeutics. The bond trades about -0.14 of its potential returns per unit of risk. The Spyre Therapeutics is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  2,844  in Spyre Therapeutics on September 12, 2024 and sell it today you would lose (195.00) from holding Spyre Therapeutics or give up 6.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.41%
Values	Daily Returns

BLK 21 25 FEB 32  vs.  Spyre Therapeutics

BLK 21 25

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days BLK 21 25 FEB 32 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, 09247XAS0 is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Spyre Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Spyre Therapeutics is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with 09247XAS0 and Spyre Therapeutics

The main advantage of trading using opposite 09247XAS0 and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 09247XAS0 position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.

The idea behind BLK 21 25 FEB 32 and Spyre Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.